Recent studies investigate Phexxi for various potential indications
Bassem Maximos, MD, MPH, FACOG, discusses 2 recent studies investigating nonhormomal contraceptive gel Phexxi (Evofem Biosciences) for the potential treatment of UTIs and improvement in sexual satisfaction.
**Editors note: In an earlier version of this video, Dr. Maximos explained that 77% of women on study/using Phexxi suffered a UTI. The data actually shows that 77 women out of 1339 study subjects suffered a UTI, a notable decrease in UTIs in women using Phexxi. The video has since been edited to reflect this correction.
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
Permanent contraception use increased in US young adults following Dobbs
January 6th 2025A recent study reported an increase in US young adults seeking permanent contraception methods following the Supreme Court’s Dobbs v Jackson Women's Health Organization decision in 2022, highlighting the need for accessible contraception.
Read More
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
